Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

? Rubius Therapeutics $RUBY has posted some positive ? though preclinical ? study results on its red blood cell tech, saying they were able to track a desired immune response using their drugs.The therapies are designed to increase the flow of T cells to a tumor, mobbing cancer cells in the process.

? Little Eidos $EIDX, which is going up against the giant Pfizer